OM:EQLHealthcare
EQL Pharma (OM:EQL): 59.6% Earnings Growth Forecast Puts Margin Narrative to the Test
EQL Pharma (OM:EQL) is projecting standout rates, with earnings forecast to climb 59.57% per year and revenue expected to grow 30.4% annually, far outpacing the Swedish market’s 3.7% revenue growth outlook. Over the past five years, the company saw earnings rise by 19.1% each year and currently holds a net profit margin of 7.4%, down from last year’s 9.9%. With a Price-to-Earnings ratio of 54.3x, EQL trades above the broader European healthcare sector but remains slightly below its immediate...